Korean J Physiol Pharmacol.  2009 Dec;13(6):417-424. 10.4196/kjpp.2009.13.6.417.

Hexane-Soluble Fraction of the Common Fig, Ficus carica, Inhibits Osteoclast Differentiation in Murine Bone Marrow-Derived Macrophages and RAW 264.7 Cells

• Park YR
• Eun JS
• Choi HJ
• Nepal M
• Kim DK
• Seo SY
• Li R
• Moon WS
• Cho NP
• Cho SD
• Bae TS
• Kim BI
• Soh Y

• KMID: 2285375
• DOI: http://doi.org/10.4196/kjpp.2009.13.6.417

Abstract

Osteoclasts, derived from multipotent myeloid progenitor cells, play homeostatic roles in skeletal modeling and remodeling, but may also destroy bone in pathological conditions such as osteoporosis and rheumatoid arthritis. Osteoclast development depends critically on a differentiation factor, the receptor activator of NF-kappaB ligand (RANKL). In this study, we found that the hexane soluble fraction of the common fig Ficus carica (HF6-FC) is a potent inhibitor of osteoclastogenesis in RANKL-stimulated RAW264.7 cells and in bone marrow-derived macrophages (BMMs). HF6-FC exerts its inhibitory effects by suppression of p38 and NF-kappaB but activation of ERK. In addition, HF6-FC significantly decreased the expression of NFATc1 and c-Fos, the master regulator of osteoclast differentiation. The data indicate that components of HF6-FC may have therapeutic effects on bone-destructive processes such as osteoporosis, rheumatoid arthritis, and periodontal bone resorption.

Keyword

Ficus carica; Osteoclast differentiation; RAW264.7 cells; Bone marrow-derived macrophages; Bone lytic diseases

MeSH Terms

Arthritis, Rheumatoid
Bone Resorption
Carica
Ficus
Macrophages
Myeloid Progenitor Cells
NF-kappa B
Osteoclasts
Osteoporosis
Receptor Activator of Nuclear Factor-kappa B
NF-kappa B
Receptor Activator of Nuclear Factor-kappa B

Figure

• 

  Fig. 1. GC/MS spectrum of HF6-FC.

• 

  Fig. 2. Effect of HF6-FC on RANKL-induced osteoclastogenesis in RAW 264.7 cells. (A) RAW 264.7 cells were cultured in the presence of RANKL (50 ng/ml) for 6 days. HF6-FC was added to the culture medium at final concentrations of 0.1, 1, and 10 μg/ml, and cells were stained for TRAP activity on day 6. (B) TRAP-positive multi-nucleated osteoclasts were counted. Data represent the mean±SD of three independent experiments. ∗p<0.05 and ∗∗p<0.01, as compared to the control without HF6-FC, respectively. (C) RAW 264.7 cells were seeded into 96-well plates and incubated with HF6-FC for 24 h. Cell proliferation was evaluated with the MTT assay.

• 

  Fig. 3. Effect of HF6-FC on RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMM). (A) BMMs were cultured in the presence of M-CSF (20 ng/ml) and RANKL (100 ng/ml) for 3 days. HF6-FC was added to the culture medium at final concentrations of 0.1, 1, and 10 μg/ml. (B) After three days, cells were fixed and stained for TRAP, and TRAP-positive multinuclear cells (MNC) were counted. Data represent the mean±SD of three independent experiments. ∗∗p<0.01 versus the control without HF6-FC.

• 

  Fig. 4. Effect of HF6-FC on MAPK activation by RANKL in RAW 264.7 cells. Cells were serum-starved for 16 h, pretreated with or without HF6-FC (10 μg/ml) for 30 min, and stimulated with RANKL (100 ng/ml) for times indicated. Whole cell lystes were used for western blotting with MAPK-specific antibodies. Blots were stripped and reprobed with other antibodies.

• 

  Fig. 5. Effect of HF6-FC on NF-κB activation by RANKL in RAW 264.7 cells. Cells were serum-starved for 16 h, pretreated with or without HF6-FC (10 μg/ml) for 30 min and stimulated with RANKL (100 ng/ml) for indicated times. Whole cell lysates were immunoblotted with antibodies specific for phospho-IκB-α and phospo-p65. Blots were stripped and reprobed with control antibodies. The histograms represent the level of the phospho-IκB-α (A) and phospo-p65 (B). The asterisk (∗) indicates a significant difference (p<0.05) compared with the control (#) at same time period.

• 

  Fig. 6. Effects of HF6-FC on c-Fos protein and NFATc1 mRNA in RANKL-stimulated RAW 264.7 cells. Cells were serum-starved for 16 h, pretreated with or without HF6-FC (10 μg/ml) for 30 min and stimulated with RANKL (100 ng/ml) for times indicated. (A) Whole cell lysates were analyzed by immunoblotting with c-Fos-and β-actin-specific antibodies. (B) NFATc1 mRNA level was determined by RT-PCR and compared with that of GAPDH. The asterisk (∗) indicates a significant difference (p<0.05) compared with the control (#) at same time period.

Reference

References

Ahmed W., Khan AQ., Malik A. Two Triterpenes from the Leaves of Ficus carica. Planta Med. 54:481. 1988.

Alliston T., Derynck R. Medicine: interfering with bone remodelling. Nature. 416:686–687. 2002.

Canal JR., Torres MD., Romero A., Pérez C. A chloroform extract obtained from a decoction of Ficus carica leaves improves the cholesterolaemic status of rats with streptootocin-includede diabetes. Acta Physiol Hung. 87:71–76. 2000.

Chang EJ., Kim HJ., Ha J., Kim HJ., Ryu J., Park KH., Kim UH., Lee ZH., Kim HM., Fisher DE., Kim HH. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci. 120:166–176. 2007.

Choi HJ., Song BJ., Gong YD., Gwak WJ., Soh Y. Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2. Br J Pharmacol. 154:114–125. 2008.

Coon D., Gulati A., Cowan C., He J. The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. J Endod. 33:432–436. 2007.

El-Kholy IS., Shaban MA. Constituents of the leaves of Ficus carica, L. II. Isolation of a psi-taraxasteryl ester, rutin, and a new steroid sapogenin. J Chem Soc Perkin. 13:1140–1142. 1966.

Han KY., Yang D., Chang EJ., Lee Y., Huang H., Sung SH., Lee ZH., Kim YC., Kim HH. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem Pharmacol. 74:911–923. 2007.

Jimi E., Aoki K., Saito H., D'Acquisto F., May MJ., Nakamura I., Sudo T., Kojima T., Okamoto F., Fukushima H., Okabe K., Ohya K., Ghosh S. Selective in hibition of NF-kappa B block osteoclastogenesis and prevents inflammatory bone destructin in vivo. Nat Med. 6:617–624. 2004.

Kobayashi N., Kadono Y., Naito A., Matsumoto K., Yamamoto T., Tanaka S., Inoue J. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO. 20:1271–1280. 2001.

Lee SE., Woo KM., Kim SY., Kim HM., Kwack K., Lee ZH., Kim HH. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone. 30:71–77. 2002.

Lee WT. Coloured standard illustrations of Korean plants. Academy press, Seoul, p 624. 1996.

Luo JL., Kamata H., Karin M. IKK/NF-kappaB signaling: balancing life and death–a new approach to cancer therapy. J Clin Invest. 115:2625–2632. 2005.

Mino T., Sugiyama E., Taki H., Kuroda A., Yamashita N., Maruyama M., Kobayashi M. Interleukin-1alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts. Arthritis Rheum. 41:2004–2013. 1998.

Miyaura C., Inada M., Matsumoto C., Ohshiba T., Uozumi N., Shimizu T., Ito A. An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J Exp Med. 197:1303–1310. 2003.

Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando MP., Asano T., Verma IM., Oda H., Nakamura K., Tanaka S. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol. 148:333–342. 2000.

Motyckova G., Weilbaecher KN., Horstmann M., Rieman DJ., Fisher DZ., Fisher DE. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A. 98:5798–5803. 2001.

Mozar A., Haren N., Chasseraud M., Louvet L., Maziere C., Wattel A., Mentaverri R., Morliere P., Kamel S., Brazier M., Maziere JC., Massy ZA. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol. 215:47–54. 2008.

Oh SY., Aryal DK., Kim YG., Kim HG. Effects of R. Glutinosa and E. Senticosus on Postmenopausal Osteoporosis. Korean J Physiol Pharmacol. 11:121–127. 2007.

Reddy SV., Hundley JE., Windle JJ., Alcantara O., Linn R., Leach RJ., Boldt DH., Roodman GD. Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res. 10:601–606. 1995.

Rubnov S., Kashman Y., Rabinowitz R., Schlesinger M., Mechoulam R. Suppressors of cancer cell proliferation from Fig (Ficus carica) Resin: isolation and structure elucidation. J Nat Prod. 64:993–996. 2001.

Serraclara A., Hawkins F., Pérez C., Domínguez E., Campillo JE., Torres MD. Hypoglycemic action of an oral fig-leaf decoction in type-I diabetic patients. Diabetes Res Clin Pract. 39:19–22. 1998.

Soh Y., Jeong KS., Lee IJ., Bae MA., Kim YC., Song BJ. Selective activation of the c-Jun N-terminal protein kinase pathway during 4-hydroxynonenal-induced apoptosis of PC12 cells. Mol Pharmacol. 58:534–541. 2000.

Soh Y., Shin MH., Lee JS., Jang JH., Kim OH., Kang H., Surh YJ. Oxidative DNA damage and glioma cell death induced by tetrahydropapaveroline. Mutat Res. 544:129–142. 2003.

Stern PH. Antiresorptive agents and osteoclast apoptosis. J Cell Biochem. 101:1087–1096. 2007.

Teitelbaum SL., Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 4:638–649. 2003.

Theill LE., Boyle WJ., Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 20:795–823. 2002.

Vaira S., Alhawagri M., Anwisye I., Kitaura H., Faccio R., Novack DV. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest. 118:2088–2097. 2008.

Wei S., Kitaura H., Zhou P., Ross FP., Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 115:282–290. 2005.

Wong BR., Besser D., Kim N., Arron JR., Vologodskaia M., Hanafusa H., Choi Y. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell. 4:1041–1049. 1999.

Wong BR., Josien R., Lee SY., Vologodskaia M., Steinman RM., Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem. 273:28355–28359. 1998.

Yamashita T., Yao Z., Li F., Zhang Q., Badell IR., Schwarz EM., Takeshita S., Wagner EF., Noda M., Matsuo K., Xing L., Boyce BF. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 282:18245–18253. 2007.

Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., Sudo T., Shultz LD., Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 345:442–444. 1990.

Zhou B., Cron RQ., Wu B., Genin A., Wang Z., Liu S., Robson P., Baldwin HS. Regulation of the murine Nfatc1 gene by NFATc2. J Biol Chem. 277:10704–10711. 2002.